Specialty Chemicals

CABIO

CABIO released FY2026 Q1 earnings on April 22 After-Market (BJT), actual revenue CNY 11.01 M, actual EPS CNY -0.26

CABIO to Release FY2026 Q1 Earnings on April 23 After-Market (BJT)

CABIO to Release FY2025 Earnings on April 23 Pre-Market (BJT), Forecast Revenue CNY 680.21 M, EPS CNY 1.075

CABIO released FY2025 Q4 earnings on February 27 Pre-Market (BJT), actual revenue CNY 135.11 M, actual EPS CNY 0.0873

CABIO released FY2025 annual earnings on February 27 Pre-Market (BJT), actual revenue CNY 563.14 M (forecast CNY 680.21 M), actual EPS CNY 0.86 (forecast CNY 1.075)

CABIO released FY2025 Q3 earnings on October 27 After-Market (BJT), actual revenue CNY 121.3 M, actual EPS CNY 0.1284

CABIO released FY2025 9 Months Earnings on October 27 After-Market (BJT), Actual Revenue CNY 428.03 M, Actual EPS CNY 0.7672

CABIO to Release FY2025 Q3 Earnings on October 28 After-Market (BJT)

CABIO released FY2025 Q2 earnings on August 18 After-Market (BJT), actual revenue CNY 150.77 M, actual EPS CNY 0.3688

CABIO released FY2025 Semi-Annual earnings on August 18 After-Market (BJT), actual revenue CNY 306.73 M, actual EPS CNY 0.64

CABIO to Release FY2025 Semi-Annual Earnings on August 19, 2025 (BJT)

Shareholder Ma Tao Plans to Reduce Shareholding in JiaBiYou

Jabiyou Premiums 4.4x to Acquire Over Half of Oebiotech's Equity

JiaBiYou's Progress in Synthetic Biology and AI Technology

Jia Bi You Shares Rise, Analysts Maintain Buy Rating

Zhao Lei of XinDa Securities Reiterates Buy Rating on CapuBio

CABIO released FY2025 Q1 earnings on April 28 After-Market (BJT), actual revenue CNY 155.97 M, actual EPS CNY 0.27

CABIO FY2025 Q1 Earnings Release Scheduled for April 29, After-Market BJT

Jabiyou Receives Buy Ratings from Multiple Brokers

Jiabiyou Expects 33.28% Revenue Growth in Q1 2025

688089

Shares of Cabio Biotech fell 11.9% after Nestlé announced a global recall of certain infant formula products due to toxin concerns linked to ARA supplied by Cabio. The recall affects specific batches in 31 countries, but Nestlé stated that the financial impact would be minimal, representing less than 0.5% of annual sales. Cabio Biotech is currently testing its products and will release results soon. The company reported a 29% revenue increase from ARA in 2024, indicating strong demand despite the recall incident.

Yicai

Nestlé's Chinese ARA Supplier Plunges After Swiss Firm Issues Global Recall of Baby Formula

CABIO, a leading Chinese biotechnology company, showcased its extensive portfolio of nutritional supplements at the 30th Food Ingredients Europe 2025 in Paris. Concurrently, CABIO announced the opening of its new global headquarters, the Wuhan Synthetic Biology Innovation Hub. This new hub aims to deepen innovation, enhance collaboration, and amplify impact in synthetic biology. CABIO's product lines include CABIO®ARA, CABIO®Omega-3, Keyshine®HMOs 2'-FL, and Keyshine®N-Acetylneuraminic Acid. The new headquarters will support CABIO's global expansion and sustainable development in the nutrition and health industry.

prnewswire

12:11 ET
			
			
			
				
					CABIO präsentiert auf der Fi Europe 2025 in Paris Innovationen im Bereich Lebensphasenernährung und eröffnet gleichzeitig seinen neuen globalen Hauptsitz

CABIO announced that the company will initiate the second phase of share repurchase in 2025, intending to repurchase shares for equity incentives with an amount ranging from 15 million to 30 million yuan. As of a certain time in 2025, a total of 1,060,573 shares have been repurchased, accounting for 0.63% of the total share capital, with a cumulative repurchase amount of 27.9213 million yuan, and the repurchase price ranging between 23.52 yuan/share and 28.58 yuan/share, in compliance with relevant regulations and repurchase plan requirements. The company will continue to advance the repurchase as required and disclose progress in a timely manner

Zhitong

CABIO: Cumulatively spent CNY 27.9213 million to repurchase 0.63% of the company's shares

CABIO announced that its revenue for the third quarter was 121 million yuan, a year-on-year decrease of 3.97%; net profit was 21.3942 million yuan, a year-on-year increase of 33.70%. Revenue for the first three quarters was 428 million yuan, a year-on-year increase of 10.56%; net profit was 129 million yuan, a year-on-year increase of 54.18%

CABIO: Third quarter net profit of 21.3942 million yuan, a year-on-year increase of 33.70%

CABIO expects a net profit attributable to the parent company of approximately 129 million yuan in the first three quarters, a year-on-year increase of 53.77%. The growth in performance is mainly attributed to the increase in sales of ARA and algal oil DHA products to domestic customers, as well as improvements in production efficiency and product structure optimization

CABIO expects a profit increase, with a projected year-on-year growth of 53.77% in net profit attributable to the parent company for the first three quarters

002910

300892

002719

002570

The dairy powder concept has seen unusual movements, with Zhuangyuan Pasture hitting the limit up, and CABIO, Knight Dairy, PINLIVE, MQR, Yiming Foods, and Beingmate also rising

Zhuangyuan Pasture

PINLIVE

Beingmate

The dairy powder concept has seen unusual fluctuations, with Zhuangyuan Pasture hitting the limit-up

688073

On September 15th, eight companies in the biopharmaceutical and CXO industries on the STAR Market held a performance briefing, using an online interactive Q&A format to address investor concerns and discuss industry ecology and development trends. Participating companies such as Bide and CABIO shared their R&D progress and global market layout, demonstrating confidence in their development for the second half of the year

Bide

Eight biopharmaceutical and CXO companies on the Sci-Tech Innovation Board gathered for a performance briefing, breaking through key technological bottlenecks became the focus of interaction

CABIO announced that on September 9, 2025, the company repurchased 428,100 shares through the Shanghai Stock Exchange trading system via centralized bidding, accounting for 0.25% of the company's current total share capital. The highest transaction price was RMB 28.58 per share, the lowest transaction price was RMB 27.25 per share, and the total transaction amount was RMB 11,999,100. This share repurchase complies with the relevant laws and regulations and the requirements of the company's second share repurchase plan

CABIO: Completed the first repurchase of 0.25% of the company's shares

CABIO(688089.SH)